

## Effect of Curcumin and Trichostatin A on the Expression of DNA Methyltransferase 1 in Hepatocellular Carcinoma Cell Line Hepa 1-6

Masumeh Sanaei MSc<sup>1</sup>, Fraidoon Kavooosi PhD<sup>1,\*</sup>

1. Research center for non-communicable diseases, Jahrom University of medical sciences, Jahrom, Iran.

Corresponding author: Fraidoon Kavooosi, PhD, Jahrom University of medical sciences, Jahrom, Fars, Iran. E-mail: kavooosifraidoon@gmail.com

Received: 03 August 2018

Accepted: 05 September 2018

### Abstract

**Background:** Hepatocellular carcinoma (HCC), primary liver cancer, is a major health problem and the third most common cause of cancer-related deaths worldwide. Epigenetic modulations are essential for the maintenance of gene expression patterns in mammals. Disruption of these processes can lead to silenced gene and malignant cellular transformation. The current study was designed to compare the effect of curcumin with trichostatin A (TSA) on DNA methyltransferase 1 (DNMT1) gene expression, cell growth inhibition, and apoptosis induction in HCC Hepa 1-6 cell line.

**Materials and Methods:** Hepatocellular carcinoma Hepa 1-6 cell line was purchased from the National Cell Bank of Iran-Pasteur Institute, treated with curcumin (1, 5, 10, 25 and 50  $\mu$ M) and TSA (0.5, 1, 2.5, 5 and 10  $\mu$ M), and the MTT assay was performed. Then, flow cytometry assay and Real-Time RT-PCR analysis were performed with curcumin and TSA treatments. Statistical comparisons between groups were performed using ANOVA (one-way ANOVA) and Turkey test. A significant difference was considered as  $P < 0.05$ .

**Results:** Both treatments showed significant inhibitory and apoptotic effects, besides reducing the expression of DNMT1. The relative expression of DNMT1 gene in the curcumin-treated groups were 0.7 to 0.3 ( $P < 0.001$ ) and in the TSA treated groups were 0.5 to 0.19 ( $P < 0.001$ ).

**Conclusion:** The curcumin and trichostatin A (TSA) can inhibit cell viability and induce apoptosis somehow through epigenetic modification. The curcumin indicated a more significant apoptotic effect than TSA.

**Keywords:** Apoptosis, Curcumin, DNMT1, Trichostatin A

### Introduction

Hepatocellular carcinoma (HCC), primary liver cancer, is a major health problem and the third most common cause of cancer-related deaths worldwide. Major risk factors and etiologies of HCC include hepatitis B virus (HBV) and hepatitis C virus (HCV). In addition to these factors, high consumption of alcohol is the prevalent cause of the HCC in developed countries (1). Epigenetic modulations, which include changes in histone modifications, DNA methylation, and alteration in microRNA (miRNA) expression without any change in the DNA sequence, are essential for the maintenance of gene expression patterns in mammals. Disruption of these processes can lead gene silencing and malignant cellular

transformation. Global epigenetic abnormalities are a hallmark of cancer. One of the most extensively studied epigenetic modifications is DNA methylation which provides a stable gene silencing mechanism, playing an important role in chromatin compaction (2). DNA methylation is achieved by a group of enzymes known as the DNA methyltransferases (DNMTs), including DNMT1, DNMT1b, DNMT1o, DNMT1p, DNMT2, DNMT3A, DNMT3b. DNMT1 maintains methyltransferase activity leads to chromatin remodeling and regulation of gene expression. Besides, DNMT3A and DNMT3b are powerful de novo methyltransferases (3). To date, natural compounds such as curcumin and epigallocatechin gallate (EGCG) have been shown to increase the sensitivity of

cancer cells to conventional agents and inhibit tumor cell growth (4). More recent studies have demonstrated that curcumin can exert its effect through epigenetic modification, including DNMTs, histone acetyltransferase (HAT), and histone deacetylase (HDAC). This agent has been known as a potential DNMT1 inhibitor resulting in hypomethylation of various genes (5, 6). Furthermore, trichostatin A (TSA), an antifungal antibiotic, is an inhibitor of HDAC activity in cultured mammalian cells which arrests cells in G1 and G2 phases of the cell cycle, induces cell differentiation, and reverts the transformed morphology of the cells in the cultured cell (7). It has been shown that HDAC inhibitor TSA in combination with curcumin has greater apoptotic and antiproliferative effects than either agent alone in breast cancer (8). Previously, we reported that TSA can inhibit proliferation and induce apoptosis by reducing the expression of DNMT1, DNMT3a, and DNMT3b in HCC HepG 2 cell line (9). Our previous results on estrogen receptor alpha (ER $\alpha$ ) in HCC HepG 2 cell line (10) and the apoptotic effect of DNA methyltransferase inhibitor genistein (GE) on HCC HepG2 (11) have encouraged us to investigate the effect of curcumin in combination to and in comparison with TSA on inactivation of DNA methyltransferase 1 gene expression, cell growth inhibition and apoptosis induction in hepatocellular carcinoma Hepa 1-6 cell line.

## Materials and Methods

### Cell culture

The current experimental study was performed in a research center for non-communicable diseases, Jahrom University of medical sciences with Ethic code of "ir.Jums.rec.1395.075". Human hepatocellular carcinoma (Hepa 1-6) cells were purchased from the National Cell Bank of Iran-Pasteur Institute and maintained in Dulbecco's modified Eagle's

medium (DMEM) supplemented with 10% fetal bovine serum, 1% antibiotics, including penicillin G sodium (Sigma), streptomycin sulfate, and amphotericin B (Sigma) at 37°C in 5% CO<sub>2</sub> to promote attachment. The cells were treated with agents (curcumin and TSA) after they attached and reached > 80 % confluence. The drugs, including curcumin and TSA were purchased from Sigma-Aldrich (St. Louis, MO, USA) and dissolved in dimethyl sulfoxide (DMSO) in order to prepare a stock solution and then all drug concentrations were prepared by diluting the stock solution. Other compounds, including fetal bovine serum (FBS), trypsin-EDTA, and phosphate-buffered saline (PBS) were purchased from the best available company and also Annexin-V-(FITC) and propidium iodide were obtained from Sigma (PI, Becton-Dickinson, San Diego, CA).

### Cell growth and viability assay

The effects of curcumin and TSA on the cell viability were measured using MTT assay. First, the cells were cultured at a density of  $5 \times 10^5$  cells per well into 96-well plates overnight and then culture medium was removed and a medium containing different concentrations of curcumin (1, 5, 10, 25 and 50  $\mu$ M) and TSA (0.5, 1, 2.5, 5 and 10  $\mu$ M) were added, controls were incubated with DMSO only. After 24, 48, and 72 h, the cells were washed twice with FBS, maintained in a medium containing MTT for 4 h, and then the culture media were discarded, 200  $\mu$ L of DMSO was added to each well and finally, the optical density was measured at 570 nm with a microplate reader.

### Cell apoptosis assay

For apoptotic effect determination, the Hepa 1-6 cells were seeded in 24-well plates at a density of  $4 \times 10^5$  cells/well and incubated for 24 h before treating with agents.

On the second day, the cells treated with curcumin (5  $\mu$ M) and TSA (2.5  $\mu$ M) based on IC50 values, at mentioned times (24, 48, and 72 h). After treatment, the culture medium was removed and all the adherent treated or untreated cells were harvested by trypsinization, washed with cold PBS, and then the cells was re-suspended in 0.5 ml of a binding buffer (1x). Finally, Annexin-V-(FITC) and propidium iodide (PI) were added to stain the cells according to the protocol and the apoptotic cells were counted by FACScan flow cytometry (Becton Dickinson, Heidelberg, Germany).

#### **Real-Time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) analysis**

To determine whether curcumin and TSA could reactivate the DNMT1 gene expression, qRT-PCR was performed. In this regard, the cells were cultured and treated with curcumin and TSA (5 and 2.5 $\mu$ M respectively, based on IC50 values) for 24, 48 and 72 h and total RNA from the cells was extracted using the RNeasy kit (Qiagen, Valencia, CA) according to the protocol and treated by RNase-free DNase (Qiagen) to eliminate the genomic DNA before cDNA synthesis. The RNA concentration and purity were determined using a BioPhotometer (Biowave II Germany). By using the RevertAid™ First Strand cDNA Synthesis Kit (Fermentas, K1622 for 100 reactions), total RNA (100 ng) was reverse transcribed to complementary DNA (cDNA) using oligo-dT primers and Superscript II Reverse Transcriptase according to the protocol. Real-time RT-PCR reactions for cDNA amplification were performed on Applied Biosystems StepOne™ Real-Time PCR System using Maxima SYBR Green

RoxqPCR master mix kit (Fermentas). DNMT1 primers were obtained from our previous work (9) which their sequences are shown in the Table I. GAPDH was used as an endogenous control. Data were analyzed using the comparative Ct ( $\Delta\Delta$ ct) method; the relative expression level of DNMT1 was calculated by determining a ratio between the amount of the gene and that of endogenous control.

#### **Statistical analysis**

The database was setup with the SPSS (version 16.0) for analysis. The data were acquired from three tests and were shown as means  $\pm$  standard deviations. Statistical comparisons between groups were performed with ANOVA (one-way ANOVA) and Turkey tests. A significant difference was considered as  $P < 0.05$ .

## **Results**

### **Effect of curcumin and TSA on viability of Hepa 1-6 cells**

The Hepa 1-6 cells were cultured in 96-well plates (at a density of  $5 \times 10^5$  per well), treated with curcumin (1, 5, 10, 25 and 50  $\mu$ M) and TSA (0.5, 1, 2.5, 5 and 10  $\mu$ M) for 1, 2, and 3 days, and evaluated by MTT assay to measure drugs effects on cell viability. The results are shown in Figure 1, comparing the percentage of cell viability in treated cells with untreated control groups. As shown in Figure 1, curcumin decreased cell viability in a time and dose-dependent manner significantly, ( $P < 0.001$ ). Similar results were observed by TSA as shown in Figure 2 ( $P < 0.001$ ). The result of MTT assay demonstrated that curcumin and TSA inhibited cell growth with an IC50 of  $\sim 5$  and  $\sim 2.5$  M $\mu$ , respectively.




Figure 1. The effect of curcumin (1, 5, 10, 25 and 50  $\mu\text{M}$ ) on the Hepa 1-6 cell viability determined by the MTT assay. Data are presented as mean  $\pm$  SD from at least triplicate wells and 3 independent experiments. Significant differences between treated cell groups and the control groups are indicated by asterisks (\*). The first column of each belongs to the control group.




Figure 2. The effect of TSA with concentrations of 0.5, 1, 2.5, 5 and 10  $\mu\text{M}$  on the Hepa 1-6 cell viability. The effect of the drug was determined by the MTT assay. Data are presented as mean  $\pm$  SD from at least triplicate wells and 3 independent experiments. Significant differences between treated cell groups and the control groups are indicated by asterisks (\*). The first column of each group belongs to the control group.

### Effect of curcumin and TSA on cell apoptosis

The propidium iodide (PI) and Annexin-V/FITC staining was done to determine the apoptotic effects of curcumin and TSA on Hepa 1-6 cells treated with curcumin (5  $\text{M}\mu$ ) and TSA (2.5  $\text{M}\mu$ ) for 24, 48, and 72 h. The cells were stained with both propidium iodide (PI) and Annexin-V/FITC in the calcium-HEPES buffer as recommended by the manufacturer protocol and the percentage of apoptotic cells was determined by flow cytometry. Flow cytometric demonstrated that both agents indicated significant apoptotic effects in all different-time treated groups as shown in the figure 3 and Figure 4 ( $P < 0.001$ ). As seen in the Figure 5, curcumin indicated a more significant apoptotic effect than TSA ( $P < 0.002$ ). The percentage of apoptotic cells were shown in table II.

### Effect of curcumin and TSA on DNMT1 gene expression

To determine the mechanism of curcumin (5  $\text{M}\mu$ ) and TSA (2.5  $\text{M}\mu$ ), RT-PCR was done to test the DNMT1 gene expression quantity during treatment with these compounds at different time periods. As shown in the Figure 6, the DNMT1 gene expression quantity was decreased significantly by treatment with curcumin and TSA. The relative expression of DNMT1 gene in the curcumin-treated groups were 0.5 ( $P < 0.003$ ), 0.3 ( $P < 0.001$ ), and 0.19 ( $P < 0.001$ ) and in the TSA treated groups were 0.7 ( $P < 0.396$ ), 0.4 ( $P < 0.004$ ), and 0.32 ( $P < 0.001$ ) at different times, respectively. The effect of curcumin was stronger than TSA.




Figure 3. Flow cytometry analysis of annexin V- (FL1-H) and PI- (FL2-H) Hepa 1-6 cell line labeled cells treated with curcumin. The cells were treated with curcumin with the concentration of 5  $\mu$ M for 24, 48, and 72 h. Data are presented as a mean  $\pm$  standard error of the mean from at least three different experiments. Asterisks (\*) indicate significant differences between treated cell groups and the control cell groups.




Figure 4. Apoptotic effect of TSA (2.5  $\mu$ M) on Hepa 1-6 cell line. The cells were treated with TSA (2.5  $\mu$ M) for 24, 48, and 72 h. Data are presented as a mean  $\pm$  standard error of the mean from at least three different experiments. Asterisks (\*) indicate significant differences between treated cell groups and the control cell groups.






Figure 5. Apoptotic effect of curcumin and TSA on Hepa 1-6 cell line

The cells were treated with curcumin (5  $\mu$ M) and TSA (2.5  $\mu$ M) for 24, 48, and 72 h. Data are presented as a mean  $\pm$  standard error of the mean from at least three different experiments. Asterisks (\*) indicate significant differences between treated cell groups and the control cell groups. Besides, the apoptotic effect of curcumin was more significant than that of the TSA.




Figure 6. The relative expression level of DNMT1. As can be seen above, curcumin (5  $\mu$ M) and TSA (2.5  $\mu$ M) decreased DNMT1 gene expression significantly. Data were analyzed using the comparative Ct ( $\Delta\Delta$ Ct) method and are presented as a mean  $\pm$  standard error of the mean from at least three different experiments. It should be noted that the effect of curcumin was stronger than TSA. Asterisks (\*) indicate significant differences between treated cells and the control group.

Table I. Real time polymerase chain reaction primers (DNMT1 and GAPDH) used in this study

Primer name	Primer name Primer sequences (5' to 3')
DNMT1	
Forward:	GAG GAA GCT GCT AAG GAC TAG TTC
Reverse:	ACT CCA CAA TTT GAT CAC TAA ATC
GAPDH	
Forward:	AAC GTG TCA GTO GTG GAC CTG
Reverse:	GGG TGT CGC TGT FGA AGT

Table II. The percentage of apoptosis in the groups treated with curcumin and TSA at different time periods.

Drug	Dose/ $\mu$ M	Duration/ h	Apoptosis %	P-value
Curcumin	5	24	17	P < 0.001
	5	48	32	P < 0.001
	5	72	45	P < 0.001
TSA	2.5	24	12	P < 0.001
	2.5	48	24	P < 0.001
	2.5	72	34	P < 0.001

## Discussion

DNA methylation plays a significant role in chromatin remodeling and transcriptional regulation in mammalian cells. DNA hypomethylation has been well documented in various cancers. Aberrant DNA methylation can be involved in tumorigenesis as a result of repression of gene transcription by methylation of the CpG islands of specific genes, such as

tumor-suppressor genes (12). In addition to hypermethylation, histone deacetylation plays a major role in tumorigenesis and is a common hallmark of human cancer (13). In mammals, DNA methylation is mediated at CpG dinucleotides by DNMTs. Histone modifications are modified by HATs and HDACs. Fortunately, epigenetic changes such as DNA hypermethylation and histone

deacetylation are reversible by DNMTs inhibitors and HDAC inhibitors (14). Previously, we indicated that DNMT1 inhibitor genistein can induce apoptosis in human HCC PLC/PRF5 (15), HepG2 (11, 16), and Hepa1-6 (17) cell lines. Besides, we reported that histone deacetylase inhibitor valproic acid can induce apoptosis in HCC WCH 17 cell line (18). Furthermore, we demonstrated that GE and trichostatin A act through inactivation of DNMT1, DNMT3a, and DNMT3b gene expression in HCC Hep G2 cell line (9).

In the present study, we indicated that curcumin and TSA can inhibit cell growth and induce apoptosis in Hepa 1-6 cells and that curcumin induces a more significant apoptotic effect than TSA. Besides, our result indicated that both agents can reduce the expression of DNMT1 significantly. The effect of curcumin on DNMT1 down-regulation was stronger than that of TSA.

Similar to our study, it has been reported that curcumin inhibits proliferation and induces apoptosis of HCC cells in a concentration-dependent manner. Other studies have shown that curcumin covalently blocks the catalytic thiolate of C1226 of DNMT1 to exert its inhibitory effect (19). One of the mechanisms of curcumin in HCC is Wnt signaling interruption by decreasing  $\beta$ -catenin activity, which suppresses the expression of  $\beta$ -catenin target genes (VEGF, c-myc, and cyclin D1) (20).

In acute myeloid leukemia (AML), curcumin reduces the expression of positive regulators of DNMT1, including p65 and Sp1, which correlates with a reduction in binding of these factors to the DNMT1 promoter region (21). Curcumin inhibits cell cycle progression and cell proliferation by accumulating cells at the G2/M-phase with a decreased expression level of DNMT1 and enhanced expression of p21 in melanoma cells (22). Another pathway of the apoptotic effect of curcumin includes NF-KB activity inhibition which leads to cellular apoptotic response (23).

As mentioned above, TSA inhibited proliferation and induced apoptosis in the current study. In agreement with our report, it has been shown that TSA increases the levels of acetylated histones H3 and H4, up-regulates liver-specific functions and liver-enriched transcription factors resulting cell growth inhibition and G0 /G1 arrest induction in both HCC HepG2 and Huh-7 (24). It has been indicated that TSA induces G2/M-phase arrest by upregulation of p21cip/waf, cyclin A, bax, and (pro)-caspase 3 and down-regulation of bcl-2 in hepatoma cells HepG2 (25). Similar studies have reported that it enhances the expression of p21, cyclin E, cyclin A, CBP, Bax, and Bak, cleaves PARP (85kDa) protein, and reduces the expression of HDAC1, E2F-1, E2F-4, p53, and hyperphosphorylated Rb protein in human oral and gastric carcinoma cell lines (26-28). In the current study, we did not evaluate the combined effect of agents and also the apoptotic factors such as expression of the cyclin-dependent kinase inhibitor p21cip1/waf1, acetylation status of p53, and phosphorylation of the cell cycle regulator retinoblastoma protein (Rb). The evaluation of these factors and the combination effect is recommended.

## Conclusion

In conclusion and in accordance with our findings, curcumin and TSA were able to restore the epigenetic regulation and appeared as attractive preventive and/or therapeutic candidates against human hepatocellular carcinoma.

## Acknowledgment

This article was supported by adjutancy of research of Jahrom medical University-Iran.

## Conflict of interest

Authors declared no conflict of interest.



## References

1. Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma—epidemiological trends and risk factors. *Dig Dis* 2009; 27(2):80-92.
2. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. *Carcinogenesis* 2010; 31(1):27-36.
3. Das PM, Singal R. DNA methylation and cancer. *J Clin. Oncol* 2004; 22(22):4632-42.
4. Reuter S, Gupta SC, Park B, Goel A, Aggarwal BB. Epigenetic changes induced by curcumin and other natural compounds. *Genes Nutr* 2011; 6(2):93-98.
5. Link A, Balaguer F, Shen Y, Lozano JJ, Leung H-CE, Boland CR, et al. Curcumin modulates DNA methylation in colorectal cancer cells. *PLoS One* 2013; 8(2): e57709-e577012.
6. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. *Cell Res* 2011; 21(3):381-395.
7. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. *Clin. Cancer. Res* 2001; 7(4):971-976.
8. Yan G, Graham K, Lanza-Jacoby S. Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells. *Mol Carcinog* 2013; 52(5):404-11.
9. Sanaei M, Kavooosi F, Roustazadeh A, Golestan F. Effect of Genistein in Comparison with Trichostatin A on Reactivation of DNMTs Genes in Hepatocellular Carcinoma. *J clin transl hepatol* 2018; 6(2):1-6.
10. Sanaei M, Kavooosi F, Salehi H. Genistein and Trichostatin A Induction of Estrogen Receptor Alpha Gene Expression, Apoptosis and Cell Growth Inhibition in Hepatocellular Carcinoma HepG 2 Cells. *APJCP* 2017; 18(12):3445-50.
11. Sanaei M, Kavooosi F, Atashpour S, Haghghat S. Effects of genistein and synergistic action in combination with tamoxifen on the HepG2 human hepatocellular carcinoma cell line. *APJCP* 2017; 18(9):2381-2391.
12. Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanishi Y, Sasako M, et al. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. *Am J Pathol* 2004; 164(2):689-699.
13. Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. *Nat Genet* 2005; 37(4):391-395.
14. Kikuchi J, Furukawa Y. DNA methyltransferase inhibitors histone deacetylase inhibitors. *Nihon Rinsho* 2014; 72(6):1136-1142.
15. Dastjerdi MN, Kavooosi F, Valiani A, Esfandiari E, Sanaei M, Sobhanian S, et al. Inhibitory effect of genistein on PLC/PRF5 hepatocellular carcinoma cell line. *Int J Prev Med* 2015; 6-10.
16. Sanaei M, Kavooosi F, Pourahmadi M, Moosavi SN. Effect of Genistein and 17-β Estradiol on the Viability and Apoptosis of Human Hepatocellular Carcinoma HepG2 cell line. *ABR* 2017; 6-10.
17. Sanaei M, Kavooosi F, Valiani A, Ghobadifar MA. Effect of genistein on apoptosis and proliferation of hepatocellular Carcinoma Hepa1-6 Cell Line. *Int J Prev Med* 2018; 9-14.
18. Kavooosi F, Sanaei M. Comparative Analysis of the Effects of Valproic Acid and Tamoxifen on Proliferation, and Apoptosis of Human Hepatocellular Carcinoma WCH 17 CellLin. *Iran J Ped Hematol Oncol* 2018; 8(1):12-20.
19. Liu Z, Xie Z, Jones W, Pavlovicz RE, Liu S, Yu J, et al. Curcumin is a potent DNA hypomethylation agent. *Bioorg Med Chem Lett* 2009; 19(3):706-709.
20. Xu MX, Zhao L, Deng C, Yang L, Wang Y, Guo T, et al. Curcumin suppresses proliferation and induces apoptosis of human hepatocellular

carcinoma cells via the wnt signaling pathway. *Int J Oncol* 2013;43(6):1951-1959.

21. Yu J, Peng Y, Wu L-C, Xie Z, Deng Y, Hughes T, et al. Curcumin down-regulates DNA methyltransferase 1 and plays an anti-leukemic role in acute myeloid leukemia. *PLoS One* 2013;8(2):e55934-e55944.

22. Abusnina A, Keravis T, Yougbaré I, Bronner C, Lugnier C. Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. *Mol Nutr Food Res* 2011;55(11):1677-1689.

23. Gall Troselj K, Novak Kujundzic R. Curcumin in combined cancer therapy. *Curr Pharm Des* 2014;20(42):668266-96.

24. Yamashita Yi, Shimada M, Harimoto Net al. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. *Int J Cancer* 2003; 103(5):572-576.

25. Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG, et al. The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. *J Hepatol* 2002;36(2):233-240.

26. Suzuki T, Yokozaki H, Kuniyasu H, Hayashi K, Naka K, Ono S, et al. Effect of trichostatin A on cell growth and expression of cell cycle-and apoptosis-related molecules in human gastric and oral carcinoma cell lines. *Int J Cancer* 2000;88(6):992-997.

27. Yan G, Graham K, Lanza-Jacoby S. Curcumin enhances the anticancer effects of trichostatin a in breast cancer cells. *Mol Carcinog* 2013;52(5):404-411.

28. Shanbhag VKL. Curcumin in chronic lymphocytic leukemia–A review. *Asian Pac J Trop Biomed* 2017; 7(6):505-512.